Drugs, not devices, star at event

Published



The majority of companies selected to present at this year’s Mid-Atlantic Bio conference were startup firms focused on therapeutic drug development. The selections, which were made by a committee drawn from venture capital firms, reflect a trend toward funding drugs, not devices.

“Products seems to be more important than platforms these days,” said Todd Brady, a principal with the Princeton, N.J.-based venture firm Domain Associates. “Drug therapeutics are becoming more important than medical devices.”

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.